Stephanie Raynish, MD
Family Medicine · Salem, OHNPI 1992190102
Payments from drug & device makers
Across 177 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$762
- Pfizer$534
- Novo Nordisk$272
- Lilly USA, LLC$254
- GSK$212
- AstraZeneca$180
- plus $690 from 16 others
What the payments were for
- Food & beverage$2,892100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $762 |
| Pfizer | 47 | $534 |
| Novo Nordisk | 17 | $272 |
| Lilly USA, LLC | 15 | $254 |
| GSK | 13 | $212 |
| AstraZeneca | 11 | $180 |
| Astellas Pharma US Inc | 5 | $91 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Amgen | 5 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Exact Sciences | 3 | $65 |
| Boehringer Ingelheim | 3 | $53 |
| Merck | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Exeltis, USA Inc. | 1 | $23 |
| Abbott | 1 | $19 |
| Organon | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,904 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $173,469 |
| EliquisApixaban | 107 | $107,600 |
| JardianceEmpagliflozin | 65 | $72,698 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $55,865 |
| MounjaroTirzepatide | 34 | $39,069 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $27,814 |
| XareltoRivaroxaban | 25 | $27,593 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $23,646 |
| TrulicityDulaglutide | 26 | $23,249 |
| Nurtec OdtRimegepant Sulfate | 11 | $21,307 |
| JanuviaSitagliptin Phosphate | 11 | $17,693 |
| GemtesaVibegron | 15 | $10,158 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 27 | $5,898 |
| Omeprazole | 310 | $3,625 |
| Gabapentin | 205 | $3,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $272 | $173,469118 claims |
| PfizerEliquis, Nurtec Odt | $534 | $128,907118 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $212 | $89,577130 claims |
| Boehringer IngelheimJardiance | $53 | $72,69865 claims |
| Lilly USA, LLCMounjaro, Trulicity | $254 | $62,31860 claims |
| MerckJanuvia | $49 | $17,69311 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $68 | $10,15815 claims |
| AbbVieSynthroid | $762 | $1,46842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Salem
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.